Ibrutinib for B cell malignancies

Experimental Hematology and Oncology

Volumn 3, Issue 1, 2014, Pages

  Novero, Aileen ^a   Ravella, Pavan M ^a   Chen, Yamei ^a,b   Dous, George ^a   Liu, Delong ^c  

^a WESTCHESTER MEDICAL CENTER   (United States)

^b XIAMEN UNIVERSITY   (China)

^c ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; BENDAMUSTINE; BORTEZOMIB; BRUTON TYROSINE KINASE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; IBRUTINIB; OFATUMUMAB; PREDNISONE; RITUXIMAB; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANEMIA; ARTHRALGIA; B CELL LEUKEMIA; B CELL LYMPHOMA; CHRONIC LYMPHATIC LEUKEMIA; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; FATIGUE; FOLLICULAR LYMPHOMA; GASTRITIS; HUMAN; INFECTION; LARGE CELL LYMPHOMA; LEUKEMIA CELL; LYMPHOCYTOPENIA; LYMPHOCYTOSIS; LYMPHOMA CELL; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MOLECULAR INTERACTION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHARMACODYNAMICS; PRIORITY JOURNAL; RASH; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION;

EID: 84978025178     PISSN: None     EISSN: 21623619     Source Type: Journal    
DOI: 10.1186/2162-3619-3-4     Document Type: Review

References (51)

1. Akinleye A, Chen Y, Mukhi N, Song Y, Liu D. Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol 2013, 6(1):59. 10.1186/1756-8722-6-59, 3751776, 23958373.
2. Mohamed AJ, Yu L, Backesjo CM, Vargas L, Faryal R, Aints A, Christensson B, Berglof A, Vihinen M, Nore BF, et al. Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev 2009, 228(1):58-73. 10.1111/j.1600-065X.2008.00741.x, 19290921.
3. Pan Z, Scheerens H, Li SJ, Schultz BE, Sprengeler PA, Burrill LC, Mendonca RV, Sweeney MD, Scott KC, Grothaus PG, et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. Chem Med Chem 2007, 2(1):58-61. 10.1002/cmdc.200600221, 17154430.
4. Cheson BD, Plass RR, Rothstein G. Defective opsonization in multiple myeloma. Blood 1980, 55(4):602-606.
5. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010, 463(7277):88-92. 10.1038/nature08638, 2845535, 20054396.
6. Tricot G, Jagannath S, Vesole D, Nelson J, Tindle S, Miller L, Cheson B, Crowley J, Barlogie B. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995, 85(2):588-596.
7. Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol 2012, 1(1):36. 10.1186/2162-3619-1-36, 3520838, 23210908.
8. Chavez JC, Sahakian E, Pinilla-Ibarz J. Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia. Core Evid 2013, 8:37-45. 3662532, 23717217.
9. Wiestner A. Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J Clin Oncol 2013, 31(1):128-130. 10.1200/JCO.2012.44.4281, 23045586.
10. Binet JL, Caligaris-Cappio F, Catovsky D, Cheson B, Davis T, Dighiero G, Dohner H, Hallek M, Hillmen P, Keating M, et al. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood 2006, 107(3):859-861.
11. Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 2012, 120(6):1175-1184. 10.1182/blood-2012-02-362624, 3418714, 22715122.
12. Nisitani S, Satterthwaite AB, Akashi K, Weissman IL, Witte ON, Wahl MI. Posttranscriptional regulation of Bruton's tyrosine kinase expression in antigen receptor-stimulated splenic B cells. Proc Natl Acad Sci USA 2000, 97(6):2737-2742. 10.1073/pnas.050583597, 15999, 10688914.
13. Vihinen M, Kwan SP, Lester T, Ochs HD, Resnick I, Valiaho J, Conley ME, Smith CI. Mutations of the human BTK gene coding for bruton tyrosine kinase in X-linked agammaglobulinemia. Hum Mutat 1999, 13(4):280-285. 10.1002/(SICI)1098-1004(1999)13:4<280::AID-HUMU3>3.0.CO;2-L, 10220140.
14. Akinleye A, Avvaru P, Furqan M, Song Y, Liu D. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol Oncol 2013, 6(1):88. 10.1186/1756-8722-6-88, 3843585, 24261963.
15. Fang X, Zhou X, Wang X. Clinical development of phosphatidylinositol 3-kinase inhibitors for non-Hodgkin lymphoma. Biomarkers Res 2013, 1(1):30.
16. Nore BF, Vargas L, Mohamed AJ, Branden LJ, Backesjo CM, Islam TC, Mattsson PT, Hultenby K, Christensson B, Smith CI. Redistribution of Bruton's tyrosine kinase by activation of phosphatidylinositol 3-kinase and Rho-family GTPases. Eur J Immunol 2000, 30(1):145-154. 10.1002/1521-4141(200001)30:1<145::AID-IMMU145>3.0.CO;2-0, 10602036.
17. Varnai P, Rother KI, Balla T. Phosphatidylinositol 3-kinase-dependent membrane association of the Bruton's tyrosine kinase pleckstrin homology domain visualized in single living cells. J Biol Chem 1999, 274(16):10983-10989. 10.1074/jbc.274.16.10983, 10196179.
18. Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci 2010, 107(29):13075-13080. 10.1073/pnas.1004594107, 2919935, 20615965.
19. Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, Flynn J, Jones J, Blum KA, Buggy JJ, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011, 117(23):6287-6296. 10.1182/blood-2011-01-328484, 3122947, 21422473.
20. Virtue A, Wang H, Yang X-F. MicroRNAs and Toll-like Receptor/Interleukin-1 Receptor Signaling. J Hematol Oncol 2012, 5(1):66. 10.1186/1756-8722-5-66, 3529674, 23078795.
21. Foa R, Guarini A. A mechanism-driven treatment for chronic lymphocytic leukemia?. N Engl J Med 2013, 369(1):85-87. 10.1056/NEJMe1303054, 23782159.
22. Advani RH, Sharman JP, Smith SM, Boyd TE, Grant BW, Kolibaba KS, Furman RR, Buggy JJ, Loury DJ, Hedrick E, et al. The BTK inhibitor PCI-32765 is highly active and well tolerated in patients with relapsed/refractory B cell malignancies: final results from a phase 1 study. Ann Oncol 2011, 22:iv135.
23. Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013, 31(1):88-94. 10.1200/JCO.2012.42.7906, 23045577.
24. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013, 369(1):32-42. 10.1056/NEJMoa1215637, 3772525, 23782158.
25. Guarini A, Chiaretti S, Tavolaro S, Maggio R, Peragine N, Citarella F, Ricciardi MR, Santangelo S, Marinelli M, De Propris MS, et al. BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgV H unmutated chronic lymphocytic leukemia (CLL) cells. Blood 2008, 112(3):782-792. 10.1182/blood-2007-12-127688, 18487510.
26. Byrd JC, Furman RR, Coutre S, Flinn IW, Burger JA, Blum KA, Sharman J, Grant B, Jones JA, Wierda WG, et al. The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) promotes high response rate, durable remissions, and is tolerable in treatment naive (TN) and relapsed or refractory (RR) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) patients including patients with high-risk (HR) disease: new and updated results of 116 patients in a phase Ib/II study. ASH Annu Meet Abstr 2012, 120(21):189.
27. Byrd JC, Blum KA, Burger JA, Coutre SE, Sharman JP, Furman RR, Flinn IW, Grant BW, Richards DA, Zhao W, et al. Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): interim results of a phase Ib/II study. J Clin Oncol 2011, 29(15):6508.
28. Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Sharman JP, Flinn IW, Grant BW, Heerema NA, Johnson AJ, et al. The Bruton's tyrosine kinase(BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients (pts): interim results of a phase Ib/II studyASCO. ASH Annu Meet Abstr 2012, 30(15):6507.
29. O'Brien S, Burger JA, Blum KA, Furman RR, Coutre SE, Sharman J, Flinn IW, Grant B, Heerema NA, Johnson AJ, et al. The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 induces durable responses in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): follow-up of a phase Ib/II study. ASH Annu Meet Abstr 2011, 118(21):983.
30. Byrd JC, Barrientos JC, Devereux S, Brown JR, Kay NE, Reddy NM, O'Brien SM, Kipps TJ, Furman RR, Schuster SJ, et al. A randomized, multicenter, open-label, phase III study of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) versus ofatumumab in patients (pts) with relapsed or refractory (RR) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): RESONATE. ASH Annu Meet Abstr 2013, 31(15_suppl):TPS8619.
31. Burger JA, Ghia P, Polliack A, Tam C, Suri D, Clow F, Kraljevic S, James DF, Kipps TJ. Randomized, multicenter, open-label, phase III study of the BTK inhibitor ibrutinib versus chlorambucil in patients 65 years or older with treatment-naive CLL/SLL (RESONATE-2, PCYC-1115-CA). ASH Annu Meet Abstr 2013, 31(15_suppl):TPS7130.
32. Zucca E, Bertoni F. Toward new treatments for mantle-cell lymphoma?. N Engl J Med 2013, 369(6):571-572. 10.1056/NEJMe1307596, 23924008.
33. Cinar M, Hamedani F, Mo Z, Cinar B, Amin HM, Alkan S. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis. Leuk Res 2013, 37(10):1271-1277. 10.1016/j.leukres.2013.07.028, 23962569.
34. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013, 369(6):507-516. 10.1056/NEJMoa1306220, 23782157.
35. Dasmahapatra G, Patel H, Dent P, Fisher RI, Friedberg J, Grant S. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib. Br J Haematol 2013, 161(1):43-56. 10.1111/bjh.12206, 23360303.
36. Edwards CM. BTK inhibition in myeloma: targeting the seed and the soil. Blood 2012, 120(9):1757-1759. 10.1182/blood-2012-07-439216, 22936735.
37. Rushworth SA, Bowles KM, Barrera LN, Murray MY, Zaitseva L, MacEwan DJ. BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB. Cell Signal 2012, 25(1):106-112.
38. Staudt LM. Chronic Active B-Cell Receptor Signaling in Lymphoma. ASH Annu Meet Abstr 2012, 120(21):26.
39. Wilson WH, Gerecitano JF, Goy A, de Vos S, Kenkre VP, Barr PM, Blum KA, Shustov AR, Advani RH, Lih J, et al. The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study. ASH Annu Meet Abstr 2012, 120(21):686.
40. Burger JA, Keating MJ, Wierda WG, Hoellenriegel J, Ferrajoli A, Faderl S, Lerner S, Zacharian G, Huang X, James DF, et al. The Btk Inhibitor Ibrutinib (PCI-32765) in Combination with Rituximab Is Well Tolerated and Displays Profound Activity in High-Risk Chronic Lymphocytic Leukemia (CLL) Patients. ASH Annu Meet Abstr 2012, 120(21):187.
41. Jaglowski SM, Jones JA, Flynn JM, Andritsos LA, Maddocks KJ, Blum KA, Grever MR, Geyer SM, Woyach JA, Johnson AJ, et al. A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. ASCO Annu Meet Abstr 2012, 30(15_suppl):6508.
42. Blum KA, Christian B, Flynn JM, Jaglowski SM, Jones JA, Maddocks K, Byrd JC. A Phase I Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Combination with Rituximab (R) and Bendamustine in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL). ASH Annu Meet Abstr 2012, 120(21):1643.
43. Younes A, Flinn I, Berdeja JG, Friedberg JW, Alberti S, Thieblemont C, Morschhauser F, Hellemans P, Hall B, Smit J, et al. Phase Ib study combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with CD20-positive B-cell non-Hodgkin lymphoma (NHL). ASCO Annu Meet Abstr 2013, 31(15_suppl):8502.
44. Cang S, Mukhi N, Wang K, Liu D. Novel CD20 monoclonal antibodies for lymphoma therapy. J Hematol Oncol 2012, 5:64. 10.1186/1756-8722-5-64, 3479003, 23057966.
45. Furqan M, Mukhi N, Lee B, Liu D. Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomarker Res 2013, 1(1):5.
46. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008, 111(12):5446-5456. 10.1182/blood-2007-06-093906, 2972576, 18216293.
47. Lu K, Wang X. Therapeutic advancement of chronic lymphocytic leukemia. J Hematol Oncol 2012, 5(1):55. 10.1186/1756-8722-5-55, 3465197, 22980425.
48. Wu M, Akinleye A, Zhu X. Novel agents for chronic lymphocytic leukemia. J Hematol Oncol 2013, 6(1):36. 10.1186/1756-8722-6-36, 3659027, 23680477.
49. Zhao Y, Huang H, Wei G. Novel agents and biomarkers for acute lymphoid leukemia. J Hematol Oncol 2013, 6(1):40. 10.1186/1756-8722-6-40, 3718656, 23773228.
50. Flinn IW, Kopecky KJ, Foucar MK, Head D, Bennett JM, Hutchison R, Corbett W, Cassileth P, Habermann T, Golomb H, et al. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 2000, 96(9):2981-2986.
51. Rushworth SA, Bowles KM, Barrera LN, Murray MY, Zaitseva L, MacEwan DJ. BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-kappaB. Cell Signal 2013, 25(1):106-112. 10.1016/j.cellsig.2012.09.008, 22975686.